Your web browser is out of date.
For your security and improved experience online, please update your browser.
Your web browser is out of date.
Diabetes on the Net is intended for healthcare professionals
Heart failure (HF) is responsible for a significant number of hospitalisations and is a leading cause of death in people with type 2 diabetes.1-4 Clinical trials have demonstrated that the SGLT2 inhibitor Forxiga reduces the risk of hospitalisation for HF,3,4 and it is now indicated in people with chronic heart failure with reduced ejection fraction (HFrEF) with or without type 2 diabetes.1
Join us for a live webinar on 31 March 2021 at 13:00 chaired by Yassir Javaid, and an expert faculty consisting of Pam Brown, Jane Diggle, Naresh Kanumilli and Nicola Milne. Alongside presenting the clinical trial data for dapagliflozin in people with HF, the practicalities of initiating dapagliflozin in this population will also be discussed. Throughout the webinar you will have the opportunity to submit your questions for a live question and answer session with the speakers immediately after the broadcast
15 minutes
Forxiga® (dapagliflozin) for managing chronic heart failure (HFrEF) in people with or without type 2 diabetes: New NICE guidance
30 minutes
Expert panel discussion:
15 minutes
Live Q&A session
Speakers
Yassir Javaid
GPwSI in Cardiology, Northampton
Pam Brown
GP in Swansea, Wales, and Welsh representative on the PCDS Committee
Jane Diggle
Practice Nurse with Specialist Interest in Diabetes, West Yorkshire
Naresh Kanumilli
Community Diabetes Consultant, Manchester
Nicola Milne
Community DSN, Manchester
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting https://aereporting.astrazeneca.com or by calling 0800 783 0033.
References
GB 27621 | March 2021
get the latest news
subscribe now
© Copyright OmniaMed Communications. All Rights Reserved
We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.